New pill RAP-103 aims to clear psoriasis in 8 weeks
NCT ID NCT07204639
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This Phase 2 trial tests whether the oral drug RAP-103 can improve skin clearance and quality of life in people with moderate to severe psoriasis. About 90 adults aged 18 to 70 will take either a daily or twice-daily dose of RAP-103 or a placebo for 8 weeks. The study measures how many achieve at least 75% skin improvement and other key outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RAP-103
- What this could lead to
- If successful, RAP-103 could offer a new oral treatment option for moderate to severe psoriasis, improving skin clearance and quality of life.
- What could go wrong
- This is an early Phase 2 proof-of-concept trial with only 90 participants. The drug may not work better than placebo, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Innovacion y Desarrollo de Estrategias en Salud
RECRUITINGMexico City, 14320, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis